PriceTargets.com logo

NASDAQ:SGTX - Sigilon Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $40.00
  • Forecasted Upside: 550.41 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$6.15 As of 09/27/2021 01:00 AM ET
▲ +0.46 (8.08%)

This chart shows the closing price for SGTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sigilon Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGTX

Analyst Price Target is $40.00
▲ +550.41% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Sigilon Therapeutics in the last 3 months. The average price target is $40.00, with a high forecast of $60.00 and a low forecast of $9.00. The average price target represents a 550.41% upside from the last price of $6.15.

This chart shows the closing price for SGTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Sigilon Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/19/2021Canaccord GenuityLower Price TargetHold ➝ Buy$62.00 ➝ $43.00Low
7/16/2021Morgan StanleyLower Price TargetEqual Weight$45.00 ➝ $9.00Low
7/9/2021Canaccord GenuityReiterated RatingBuy$62.00High
1/8/2021Canaccord GenuityInitiated CoverageBuy$62.00Low
12/29/2020BarclaysInitiated CoverageOverweight$48.00N/A
12/29/2020Morgan StanleyInitiated CoverageEqual Weight$45.00N/A
12/29/2020Jefferies Financial GroupInitiated CoverageBuy$60.00N/A
(Data available from 9/28/2016 forward)

News Sentiment Rating

0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2021
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
7/30/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/29/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/28/2021

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Sigilon Therapeutics logo
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $6.15
Low: $5.56
High: $6.21

50 Day Range

MA: $5.49
Low: $4.42
High: $6.47

52 Week Range

Now: $6.15
Low: $4.33
High: $54.32

Volume

97,646 shs

Average Volume

182,581 shs

Market Capitalization

$197.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Sigilon Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Sigilon Therapeutics in the last year: Barclays PLC, Canaccord Genuity, Jefferies Financial Group Inc., Morgan Stanley, and Zacks Investment Research.
View the latest analyst ratings for SGTX.

What is the current price target for Sigilon Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Sigilon Therapeutics in the last year. Their average twelve-month price target is $40.00, suggesting a possible upside of 550.4%. Jefferies Financial Group Inc. has the highest price target set, predicting SGTX will reach $60.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $9.00 for Sigilon Therapeutics in the next year.
View the latest price targets for SGTX.

What is the current consensus analyst rating for Sigilon Therapeutics?

Sigilon Therapeutics currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SGTX will outperform the market and that investors should add to their positions of Sigilon Therapeutics.
View the latest ratings for SGTX.

What other companies compete with Sigilon Therapeutics?

Other companies that are similar to Sigilon Therapeutics include OraSure Technologies, Taysha Gene Therapies, Nyxoah, SI-BONE, Oramed Pharmaceuticals, Lexicon Pharmaceuticals, Amryt Pharma, Curis, Rapid Micro Biosystems, Orthofix Medical, Surmodics, Shattuck Labs, PAVmed, Precision BioSciences and PetIQ.